Gilead Sciences, Inc. (NASDAQ: GILD) ended the regular session on Monday, December 22, 2025 essentially flat, and the stock showed only a modest change in post-market trading—yet the news flow behind the scenes was anything but quiet.
After the closing bell, investors were digesting a fresh antiviral pipeline update tied to a new genital herpes program, plus a newly confirmed appearance at January’s heavyweight healthcare investor conference—both of which can shape sentiment as markets reopen on Tuesday, December 23, 2025.
GILD after-hours check: where the stock stands tonight
Here’s the key price action from Monday’s session and the after-hours tape:
- Close (Dec. 22):$124.16 (down 0.10%)
- After-hours (as of 7:55 p.m. ET):$124.35 (up about 0.15% vs. the close)
- Day’s range:$122.84 – $124.90
- Volume: ~6.52 million shares
- Market cap (approx.):$154B as of Dec. 22
The headline: after-hours trading is calm so far, but Monday’s corporate updates carry longer-term implications that can matter more than a single evening’s price flicker.
The big story after the bell: Gilead expands its antiviral pipeline with an HSV move
The most market-relevant “today” headline came from Gilead’s decision to move deeper into a new antiviral area. On December 22, Gilead announced it has exercised its option to exclusively license Assembly Biosciences’ herpes simplex virus (HSV) helicase‑primase inhibitor programs, including investigational candidates ABI‑1179 and ABI‑5366, aimed at recurrent genital herpes. Gilead+1
Why this matters to investors
Gilead framed the move as part of building a “novel antiviral pipeline,” and highlighted the real-world size of the unmet need: the company said over four million people in the U.S. and major European countries experience recurrent genital herpes, and that no new HSV therapies have been approved in the U.S. or Europe for more than 25 years. Gilead
Just as important, Gilead pointed to early clinical signals that support the strategic logic:
- Positive interim Phase 1b data for ABI‑5366 and ABI‑1179 showing “strong antiviral activity” and improvements in clinical outcomes (including reduced virus-positive lesions), according to the company. Gilead+1
- Pharmacokinetic and safety profiles described as supportive of once‑weekly oral dosing—a potential differentiator if the programs continue to progress.
Deal terms: what Gilead is paying for optionality
Under the collaboration structure, Assembly Bio is set to receive a $35 million payment for Gilead’s option exercise, and could be eligible for up to $330 million in regulatory and commercial milestones, plus tiered royalties on net sales (with an alternative profit-share option in the U.S.).
Reuters’ item feed also highlighted the $35 million payment tied to the option exercise.
Investor takeaway: this is not a near-term revenue event—these are investigational programs—but it’s a notable signal about where Gilead is placing incremental R&D bets: expanding antivirals beyond its core HIV franchise and looking for differentiated dosing profiles that could stand out clinically and commercially.
Another “today” catalyst: Gilead confirms a major January investor conference appearance
Gilead also announced Monday that executives will present at the J.P. Morgan Healthcare Conference on Monday, January 12, 2026, starting at 11:15 a.m. Pacific Time, with a webcast available via the company’s investor relations site.
Why that matters before Tuesday’s open: JPM week is one of the market’s biggest annual catalysts for large-cap biotech and pharma, often driving:
- pipeline and trial-update expectations,
- guidance and capital allocation framing,
- partnership/M&A speculation (even if nothing is announced).
Even a routine conference appearance can move a stock if investors think management will provide sharper 2026 signposts—or if competitors’ updates shift the narrative across the sector.
Today’s forecasts and analyst view: what Wall Street is implying for GILD
A widely followed baseline for “forecast” coverage is the Street’s consensus price target.
As of today’s compiled analyst snapshot, 20 analysts covering Gilead show:
- Consensus rating:Buy
- Average 12-month target:$127.60
- Range:$96 (low) to $151 (high)
At Monday’s closing level, that consensus implies modest upside over the next year—not an “all clear,” but a signal that analysts broadly still view Gilead as supported by durable cash flows and pipeline optionality.
A notable theme in today’s commentary: “steady HIV + improving oncology”
In a separate “today” market note summarizing JPMorgan’s large-cap pharma views, JPMorgan characterized Gilead as offering a balanced risk-reward, supported by stable HIV cash flows and “improving oncology prospects,” while suggesting the stock may “re-rate only gradually” until there’s clearer evidence of sustained oncology-led growth. Investing.com
That framework helps explain why the stock can trade calmly even when Gilead publishes meaningful pipeline steps: the market may be waiting for bigger inflection points (late-stage data, approvals, or clearer traction across newer franchises).
What to know before the market opens Tuesday, Dec. 23, 2025
Here’s a practical, investor-focused checklist for the next session.
1) Watch for follow-through analyst notes on the HSV licensing move
The question for Tuesday isn’t whether HSV is a large market in theory—it’s what probability the Street assigns to:
- successful advancement beyond Phase 1b,
- differentiation versus existing suppressive therapies,
- commercial willingness to adopt a new regimen.
If analysts publish new commentary, it can change the tone quickly even if after-hours trading was muted.
2) Know the technical context: GILD is near the upper end of its yearly range
Gilead is trading closer to its highs than its lows, which can matter in a low-liquidity, headline-driven week:
- 52-week range:$88.57 – $128.70
- Monday’s intraday low:$122.84 (a near-term reference level traders often watch)
This doesn’t predict direction—but it explains why the stock can become more sensitive to incremental news when it’s within striking distance of a recent high.
3) Calendar risk: holiday week trading can exaggerate moves
Liquidity tends to thin out into late December. That matters because it can amplify price swings on relatively small headlines—especially in healthcare, where policy, trial updates, and deal chatter can surface unexpectedly.
Also, U.S. exchanges indicated they will remain open on Dec. 24 and Dec. 26, with an early close on Dec. 24 and a regular full day on Dec. 26, per Reuters.
That schedule can concentrate positioning decisions into fewer, choppier sessions.
4) Look ahead: the next earnings “gravity point”
For many investors, the next major catalyst after conference season is earnings. Market calendars widely point to Tuesday, Feb. 10, 2026 as the estimated next earnings date for Gilead (company confirmation can change this).
Between now and then, the market will be particularly sensitive to:
- any updates that reinforce (or undermine) the HIV durability narrative,
- evidence of acceleration in oncology,
- and the pace of pipeline progress in newer antiviral areas like HSV.
The bottom line for tonight
Gilead stock is only slightly higher in after-hours trading after a near-flat close—but the fundamental focus sharpened on Monday: Gilead is putting more weight behind its next-wave antiviral pipeline via the Assembly HSV programs, while also setting the stage for fresh investor attention at the J.P. Morgan Healthcare Conference in mid-January.
For Tuesday’s open, the most important “tell” will be whether the market treats the HSV move as a meaningful pipeline catalyst (even early-stage) or as a longer-duration option that doesn’t change near-term valuation.
This article is for informational purposes only and is not financial advice.
